A systematic review has identified fourteen cases of non-feline sporotrichosis linked with insect bites. Sporothrix schenckii was identified in six cases; the species was not determined in the remainder. The infection sites identified in some of the cases were the upper extremity (two cases), face (one case), lower extremity (2 cases), and left arm (one […]
Aspergillus IgG levels, a predictive tool for relapse in chronic pulmonary aspergillosis patients
A retrospective analysis of chronic pulmonary aspergillosis (CPA) patients has demonstrated the presence of Aspergillus sensitisation and a higher Aspergillus-specific IgG titre at completion of antifungal treatment as predictors of relapse. Contrastingly, no significant association was found between relapse and underlying lung conditions such as chronic obstructive pulmonary disease or prior TB. This finding will […]
Nosocomial transmission of Candida auris blocked in the Netherlands by infection control
A total of 26 isolates (cases) of C. auris have been reported in the Netherlands, from first appearance in 2018 to 2025; two cases were invasive infections, while the remaining twenty-four cases were regarded as colonisation. All were imported cases. Since the first report of C. auris in the Netherlands, an upward trend in the […]
Isavuconazole, a suitable alternative for first-line treatment of invasive fungal disease in children
A Spanish paediatric case series, published in the Journal of Antimicrobial Chemotherapy, has demonstrated the safety and effectiveness of isavuconazole in treating invasive fungal disease (IFD) in children. Mendosa-Palomar et al. retrospectively analyzed 107 children (≤18 years) from nine public teaching hospitals in Spain, of whom isavuconazole was prescribed as treatment in 95 patients (89%) […]
Should invasive pulmonary aspergillosis in patients with liver failure preclude liver transplant?
Invasive pulmonary aspergillosis (IPA) before liver transplantation increases mortality post-transplant by ~4x, according to Fang Chen and colleagues. Mortality with and without IPA was 38.1% vs 10.5% at 3 months (p= 0.049) and 42.9% vs 10.5% at 12 months (p = 0.026), respectively. These high mortality figures were despite antifungal therapy in 67% for a median […]
Albumin binding of fatty acids protects mammals from pulmonary mucormycosis
Mucormycosis especially affects those with poorly controlled diabetes, neutropenia and those with iron overload, as well as trauma victims. The immune defence against mucormycosis has long been assumed to be similar to that against other mould infections, but this is not the case. A remarkable and huge piece of translational pathogenesis work coordinated by Georgios […]
Is the prognosis of patients with fungal keratitis better with natamycin 5% plus voriconazole 1% combined compared with natamycin monotherapy?
A clinical trial conducted in India has reported that adjunctive topical voriconazole did not significantly improve clinical outcomes compared with natamycin 5% monotherapy. Di Zazzo and colleagues compared complete ulcer resolution with medical therapy and time to epithelial healing amongst 108 adults randomised 1:1 to receive either natamycin 5% plus voriconazole 1% (combination therapy) or natamycin 5% plus placebo […]
Fungal ball of the sinus – usually a benign long-term course without surgery
A remarkable paper from Itai Margulis and colleagues in Petah Tikva, Israel, identified an incidental fungus ball in the sinuses of 83 patients among 108,360 head CT scans (0.075%) over 12 years. The maxillary sinus was involved in 42 (50.6%), and the sphenoid in 36 (43.4%) patients and 81 (97.6%) were unilateral. Most of the patients were older people, with a […]
Is voriconazole superior to itraconazole in chronic pulmonary aspergillosis treatment?
A recent Indian study has shown that there is no difference in the proportion of patients with chronic pulmonary aspergillosis (CPA) who experience a favourable response following treatment with either itraconazole or voriconazole. The study also found similar rates of relapse in chronic pulmonary aspergillosis across the two groups. However, significantly more adverse events were associated […]
Isavuconazole therapy in critically ill adult patients with invasive aspergillosis showed a lower mortality compared with previous estimates
An Italian prospective, multicentre study by Giacobbe et al. showed a crude mortality rate of 44.0% at 30 days and 62.2% at 90 days in patients with proven or probable invasive aspergillosis receiving isavuconazole treatment while under intensive care. This was lower than rates reported in most of the current literature. A study conducted in […]